A case series of serious and unexpected adverse drug reactions under treatment with cariprazine

Reporting of new or unexpected adverse drug reactions of medicines that are subject to additional monitoring (“black triangle” label), such as the antipsychotic drug cariprazine, is of paramount importance to improve pharmacotherapy safety. Reporting of new or unexpected adverse drug reactions of me...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 9; no. 5; pp. e04084 - n/a
Main Authors Heck, Johannes, Seifert, Johanna, Stichtenoth, Dirk O., Schroeder, Christoph, Groh, Adrian, Szycik, Gregor R., Degner, Detlef, Adamovic, Ivana, Schneider, Michael, Glocker, Catherine, Rüther, Eckart, Bleich, Stefan, Grohmann, Renate, Toto, Sermin
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.05.2021
John Wiley and Sons Inc
Wiley
Subjects
adverse drug reactions
Anesthesia
cariprazine
Case Report
Case Reports
Dopamine
dopamine supersensitivity psychosis
Drug dosages
drug safety
Hospitalization
hyperprolactinemia
Patient safety
Psychosis
Psychotropic drugs
Schizophrenia
Substance abuse treatment
United States > US
Germany
adverse drug reactions
hyperprolactinemia
cariprazine
dopamine supersensitivity psychosis
drug safety
Online AccessGet full text

Cover

More Information
Summary:Reporting of new or unexpected adverse drug reactions of medicines that are subject to additional monitoring (“black triangle” label), such as the antipsychotic drug cariprazine, is of paramount importance to improve pharmacotherapy safety. Reporting of new or unexpected adverse drug reactions of medicines that are subject to additional monitoring (“black triangle” label), such as the antipsychotic drug cariprazine, is of paramount importance to improve pharmacotherapy safety.
Bibliography:Johannes Heck and Johanna Seifert have contributed equally to this work.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.4084